Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

NCT06144944 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Invasive
Hormone-receptor-positive Breast Cancer
HER2 Low Breast Carcinoma
Early-stage Breast Cancer

Interventions

DRUG: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
DRUG: Epirubicin or doxorubicin, cyclophosphamide, paclitaxel

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborators

[object Object]